{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T06:21:23Z","timestamp":1769754083337,"version":"3.49.0"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Meningococcal meningitis poses a significant public health burden in the meningitis belt region of sub-Saharan Africa. The introduction of the meningococcal PsA-TT vaccine (MenAfriVac\u00ae) has successfully eliminated <jats:italic>Neisseria meningitidis<\/jats:italic> serogroup A (NmA) cases in the region. However, the duration of post-vaccination immunity and the need for booster doses remain uncertain. To address this knowledge gap, we developed computational models using machine learning techniques to improve the effectiveness of modeling in guiding vaccination strategies for the African meningitis belt. Using serologic data from previous clinical trials of PsA-TT, we proposed a short-term and a long-term model that integrated demographic and medical variables (such as age, height and weight) with previous antibody titer levels and vaccination information to predict NmA antibody titer levels following vaccination. In the short-term model, we found moderately high performance (R-squared\u2009=\u20090.59) for out-of-training-data subjects and even better performance (R squared\u2009=\u20090.83) in the long-term evaluation. Our models estimated the half-life of the vaccine to be 13.9 years for the study population overall, similar to previously reported estimates. Machine learning techniques offer several advantages over previous approaches, as they do not require multiple readings from the same subject, can be rigorously validated using a subset of subject data not used for training. The proposed approach also facilitates the interpretation of the relationship between input variables and antibody levels at a population level. By incorporating subject-specific demographic and medical variables, our models could potentially be used to tailor vaccination schedules to at-risk populations.<\/jats:p>","DOI":"10.1371\/journal.pone.0323384","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T18:04:00Z","timestamp":1747245840000},"page":"e0323384","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Modeling protective meningococcal antibody responses and factors influencing antibody persistence following vaccination with MenAfriVac using machine learning"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3955-0996","authenticated-orcid":true,"given":"Md","family":"Nasir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William B.","family":"Weeks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrzad","family":"Gholami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Marfin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Alderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Troy","family":"Leader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0474-4708","authenticated-orcid":true,"given":"Brian","family":"Taliesin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3812-3906","authenticated-orcid":true,"given":"Rahul","family":"Dodhia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Lavista Ferres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niranjan","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"issue":"6","key":"pone.0323384.ref001","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1365-3156.2006.01639.x","article-title":"Editorial: 100 years of epidemic meningitis in West Africa - has anything changed?","volume":"11","author":"B Greenwood","year":"2006","journal-title":"Trop Med Int Health"},{"issue":"2","key":"pone.0323384.ref002","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3390\/microorganisms9020377","article-title":"The global burden of meningitis in children: challenges with interpreting global health estimates","volume":"9","author":"C Wright","year":"2021","journal-title":"Microorganisms"},{"issue":"3","key":"pone.0323384.ref003","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0035-9203(02)90089-1","article-title":"Where is the meningitis belt? Defining an area at risk of epidemic meningitis in Africa","volume":"96","author":"AM Molesworth","year":"2002","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"pone.0323384.ref004","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiz358","article-title":"Bacterial meningitis epidemiology in five countries in the meningitis belt of Sub-Saharan Africa, 2015\u20132017","volume":"220","author":"HM Soeters","year":"2019","journal-title":"J Infect Dis"},{"key":"pone.0323384.ref005","article-title":"Case-fatality ratio of bacterial meningitis in the African meningitis belt: we can do better","author":"P Boisier","year":"2007","journal-title":"Vaccine"},{"key":"pone.0323384.ref006","article-title":"Antibody persistence at 1 and 4 years following a single dose of MenAfriVac or quadrivalent polysaccharide vaccine in healthy subjects aged 2-29 years","author":"A Diallo","year":"2015","journal-title":"Clin Infect Dis"},{"key":"pone.0323384.ref007","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S1473-3099(17)30301-8","article-title":"Impact of MenAfriVac in nine countries of the African meningitis belt, 2010\u201315: an analysis of surveillance data","volume":"17","author":"CL Trotter","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"pone.0323384.ref008","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/civ518","article-title":"Antibody persistence at 1 and 4 years following a single dose of MenAfriVac or quadrivalent polysaccharide vaccine in healthy subjects aged 2\u201329 years","volume":"61","author":"A Diallo","year":"2015","journal-title":"Clin Infect Dis"},{"key":"pone.0323384.ref009"},{"key":"pone.0323384.ref010"},{"key":"pone.0323384.ref011","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/civ672","article-title":"Antibody persistence 1\u20135 years following vaccination with MenAfriVac in African children vaccinated at 12\u201323 months of age","volume":"61","author":"MD Tapia","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pone.0323384.ref012","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1473-3099(18)30674-1","article-title":"Antibody kinetics following vaccination with MenAfriVac: an analysis of serological data from randomised trials","volume":"19","author":"M White","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"24","key":"pone.0323384.ref013","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1003812","article-title":"Immunogenicity and safety of a meningococcal a conjugate vaccine in Africans","volume":"364","author":"SO Sow","year":"2011","journal-title":"N Engl J Med"},{"key":"pone.0323384.ref014","volume-title":"Results from the MenA conjugate vaccine (PsA-TT) randomized controlled trials in infants and young children","author":"Meningitis Vaccine Project & Partners","year":"2014"},{"issue":"6","key":"pone.0323384.ref015","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1084\/jem.162.6.1837","article-title":"Escherichia coli K51 and K93 capsular polysaccharides are crossreactive with the group A capsular polysaccharide of Neisseria meningitidis. Immunochemical, biological, and epidemiological studies","volume":"162","author":"N Guirguis","year":"1985","journal-title":"J Exp Med"},{"issue":"5","key":"pone.0323384.ref016","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1128\/iai.6.5.651-656.1972","article-title":"Enteric bacteria cross-reactive with Neisseria meningitidis groups A and C and Diplococcus pneumoniae types I and 3","volume":"6","author":"JB Robbins","year":"1972","journal-title":"Infect Immun"},{"issue":"6","key":"pone.0323384.ref017","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1128\/iai.13.6.1654-1662.1976","article-title":"Bacillus pumilus polysaccharide cross-reactive with meningococcal group A polysaccharide","volume":"13","author":"WF Vann","year":"1976","journal-title":"Infect Immun"},{"issue":"2","key":"pone.0323384.ref018","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/cdli.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group","volume":"4","author":"SE Maslanka","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"pone.0323384.ref019","unstructured":"Nori H, Jenkins S, Koch P, Caruana R. InterpretML: A Unified Framework for Machine Learning Interpretability. 2019. [cited 4 May 2023]. Available from: https:\/\/arxiv.org\/abs\/1909.09223v1"},{"key":"pone.0323384.ref020","first-page":"3149","article-title":"LightGBM: a highly efficient gradient boosting decision tree","volume-title":"Proceedings of the 31st International Conference on Neural Information Processing Systems.","author":"G Ke","year":"2017"},{"key":"pone.0323384.ref021","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1145\/2939672.2939785","article-title":"XGBoost: A Scalable Tree Boosting System.","volume-title":"Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining","author":"T Chen","year":"2016"},{"issue":"5","key":"pone.0323384.ref022","first-page":"780","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England","volume":"10","author":"N Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"issue":"11","key":"pone.0323384.ref023","doi-asserted-by":"crossref","first-page":"881","DOI":"10.4161\/hv.6.11.12849","article-title":"Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo\u00ae) or Menactra\u00ae among healthy adolescents","volume":"6","author":"CJ Gill","year":"2010","journal-title":"Hum Vaccin"},{"issue":"6","key":"pone.0323384.ref024","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2014.02.025","article-title":"Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents","volume":"164","author":"R Baxter","year":"2014","journal-title":"J Pediatr"},{"issue":"5","key":"pone.0323384.ref025","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1080\/21645515.2015.1136040","article-title":"Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants","volume":"12","author":"R Baxter","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"pone.0323384.ref026","article-title":"Influence of Age on Antibody Response and Persistence Following Immunization With MenAfriVac","author":"Y Tang","year":"2015","journal-title":"Clin Infect Dis"},{"key":"pone.0323384.ref027"},{"key":"pone.0323384.ref028"},{"key":"pone.0323384.ref029","author":"Mondiale de la Sant\u00e9 O","year":"2024"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0323384","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T18:04:12Z","timestamp":1747245852000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0323384"}},"subtitle":[],"editor":[{"given":"Oyelola A.","family":"Adegboye","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0323384","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]}}}